Ascendis Pharma A/S vs Booz Allen Hamilton Holding Corporation — how do they compare? Ascendis Pharma A/S trades at $253.76 (market cap $16.67B), while Booz Allen Hamilton Holding Corporation trades at $78.21 (market cap $9.45B). The key difference: Ascendis Pharma A/S is the larger of the two by market cap, and Booz Allen Hamilton Holding Corporation pays a 3% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | BAH | |
|---|---|---|
Market Cap | $16.67B | $9.45B |
Sector | Health | Industrials |
52-Week High | $277.18 | $111.63 |
52-Week Low | $189.74 | $59.71 |
Enterprise Value | $17.04B | $13.07B |
Dividend Yield | — | 3% |
Trailing returns across standard periods
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →Booz Allen Hamilton Holding Corp is a provider of management consulting services to the U.S. government. Other services offered include technology, such as cloud computing and cybersecurity consulting, and engineering consulting. The consulting services are focused on defense, intelligence, and civil markets. In addition to the U.S. government, Booz Allen Hamilton provides its management and technology consulting services to large corporations, institutions, and nonprofit organizations. The company assists clients in long-term engagements around the globe.
Read more on BAH →